Entera Bio Ltd Financials
Entera Bio Ltd (ENTX) reported $42K in revenue for fiscal year 2025, down 76.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not sales, is sustaining an asset-light development model where research spend determines cash burn.
Because free cash flow almost matched operating cash flow in the latest year—-$7.5M versus-$7.4M —the business is not being drained by heavy capital spending; cash use is coming from operating burn. The rebound in total assets to$16.0M came with$13.7M of financing inflow and a larger share count, so the stronger balance sheet was externally funded rather than produced by revenue.
The company still carries a liquid, lightly levered balance sheet, with a current ratio of 6.9x and liabilities that are modest relative to assets. But with only
R&D remains the real operating engine: research spending was
Financial Health Signals
Entera Bio Ltd does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Entera Bio Ltd scores 102.22, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($552.3M) relative to total liabilities ($2.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Entera Bio Ltd passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Entera Bio Ltd reported a net loss of $11.4M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Entera Bio Ltd generated $42K in revenue in fiscal year 2025. This represents a decrease of 76.8% from the prior year.
Entera Bio Ltd's EBITDA was -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.5% from the prior year.
Entera Bio Ltd reported -$11.4M in net income in fiscal year 2025. This represents a decrease of 19.9% from the prior year.
Entera Bio Ltd earned $0.25 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.
Cash & Balance Sheet
Entera Bio Ltd recorded an outflow of $7.5M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 9.6% from the prior year.
Entera Bio Ltd held $7.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Entera Bio Ltd's gross margin was 0.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 5.0 percentage points from the prior year.
Entera Bio Ltd's ROE was -87.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 30.8 percentage points from the prior year.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Entera Bio Ltd invested $6.0M in research and development in fiscal year 2025. This represents an increase of 33.5% from the prior year.
Entera Bio Ltd invested $107K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3466.7% from the prior year.
Not reported for fiscal year 2025.
ENTX Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | N/A | $0 | $0-100.0% | $42K | N/A | $42K |
| Cost of Revenue | $0 | $0 | N/A | $0 | $0-100.0% | $42K | N/A | $42K |
| Gross Profit | $0 | $0 | N/A | $0 | $0 | $0 | N/A | $0 |
| R&D Expenses | $3.2M+42.2% | $2.3M | N/A | $1.6M+8.1% | $1.5M+35.4% | $1.1M | N/A | $1.5M |
| SG&A Expenses | $124K-3.1% | $128K | N/A | $122K+18.4% | $103K-16.3% | $123K | N/A | $62K |
| Operating Income | -$4.6M-28.9% | -$3.5M | N/A | -$3.3M-22.0% | -$2.7M-4.1% | -$2.6M | N/A | -$3.0M |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Net Income | -$7.3M-108.6% | -$3.5M | N/A | -$3.2M-20.5% | -$2.7M-3.5% | -$2.6M | N/A | -$3.0M |
| EPS (Diluted) | $0.14 | $0.070.0% | $0.070.0% | $0.07+16.7% | $0.060.0% | $0.060.0% | $0.06-25.0% | $0.08 |
Not reported in any period shown, so not listed: Interest Expense.
ENTX Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $19.5M+48.4% | $13.1M-17.9% | $16.0M-8.1% | $17.4M-11.5% | $19.7M-8.9% | $21.6M+130.0% | $9.4M+21.3% | $7.7M |
| Current Assets | $18.9M+51.3% | $12.5M-18.3% | $15.3M-10.0% | $17.0M-11.9% | $19.3M-9.0% | $21.2M+136.5% | $9.0M+22.2% | $7.3M |
| Cash & Equivalents | $11.3M+173.4% | $4.1M-41.8% | $7.1M-17.1% | $8.6M-21.0% | $10.9M-13.6% | $12.6M+45.2% | $8.7M+25.2% | $6.9M |
| Accounts Receivable | N/A | N/A | $0 | $0 | $0-100.0% | $126K0.0% | $126K+200.0% | $42K |
| Total Liabilities | $12.2M+400.2% | $2.4M-15.6% | $2.9M+33.1% | $2.2M-9.9% | $2.4M+8.6% | $2.2M+69.5% | $1.3M+1.6% | $1.3M |
| Current Liabilities | $2.1M+33.5% | $1.6M-28.5% | $2.2M+40.2% | $1.6M-14.8% | $1.8M+13.6% | $1.6M+38.0% | $1.2M+5.9% | $1.1M |
| Total Equity | $7.3M-32.0% | $10.7M-18.4% | $13.1M-14.0% | $15.2M-11.7% | $17.3M-11.0% | $19.4M+139.8% | $8.1M+25.2% | $6.5M |
| Retained Earnings | -$136.2M-5.7% | -$128.9M-2.8% | -$125.4M-2.5% | -$122.3M-2.7% | -$119.2M-2.3% | -$116.5M-2.3% | -$113.9M-2.1% | -$111.6M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
ENTX Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.5M-12.1% | -$3.1M-68.6% | -$1.8M+26.7% | -$2.5M-53.4% | -$1.6M-16.2% | -$1.4M+4.3% | -$1.5M+31.9% | -$2.2M |
| Capital Expenditures | $3K | $0-100.0% | $27K-37.2% | $43K+48.3% | $29K+262.5% | $8K+166.7% | $3K | $0 |
| Free Cash Flow | -$3.5M-12.2% | -$3.1M-66.1% | -$1.9M+26.9% | -$2.5M-53.3% | -$1.7M-17.6% | -$1.4M+3.9% | -$1.5M+31.8% | -$2.2M |
| Investing Cash Flow | -$3K | $0+100.0% | -$27K+37.2% | -$43K-48.3% | -$29K-262.5% | -$8K-166.7% | -$3K | $0 |
| Financing Cash Flow | $10.0M+7560.8% | $130K-25.3% | $174K-30.4% | $250K+590.2% | -$51K-100.4% | $13.3M+314.6% | $3.2M+24646.2% | $13K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
ENTX Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 0.0% | N/A | 0.0% |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | -6102.4% | N/A | -7192.9% |
| Net Margin | N/A | N/A | N/A | N/A | N/A | -6111.9% | N/A | -7192.9% |
| Return on Equity | -100.6%-67.8pp | -32.8% | N/A | -21.0%-5.6pp | -15.4%-2.1pp | -13.3% | N/A | -46.8% |
| Return on Assets | -37.5%-10.8pp | -26.7% | N/A | -18.4%-4.9pp | -13.5%-1.6pp | -11.9% | N/A | -39.0% |
| Current Ratio | 8.98+1.1x | 7.93+1.0x | 6.94-3.9x | 10.83+0.4x | 10.47-2.6x | 13.07+5.4x | 7.63+1.0x | 6.61 |
| Debt-to-Equity | 1.68+1.5x | 0.230.0x | 0.22+0.1x | 0.140.0x | 0.140.0x | 0.110.0x | 0.160.0x | 0.20 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | -3361.9% | N/A | -5128.6% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Entera Bio Ltd Ranks
Frequently Asked Questions
What is Entera Bio Ltd's annual revenue?
Entera Bio Ltd (ENTX) reported $42K in total revenue for fiscal year 2025. This represents a -76.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Entera Bio Ltd's revenue growing?
Entera Bio Ltd (ENTX) revenue declined by 76.8% year-over-year, from $181K to $42K in fiscal year 2025.
Is Entera Bio Ltd profitable?
No, Entera Bio Ltd (ENTX) reported a net income of -$11.4M in fiscal year 2025.
What is Entera Bio Ltd's EBITDA?
Entera Bio Ltd (ENTX) had EBITDA of -$11.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Entera Bio Ltd's gross margin?
Entera Bio Ltd (ENTX) had a gross margin of 0.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Entera Bio Ltd's return on equity (ROE)?
Entera Bio Ltd (ENTX) has a return on equity of -87.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Entera Bio Ltd's free cash flow?
Entera Bio Ltd (ENTX) recorded an outflow of $7.5M in free cash flow during fiscal year 2025. This represents a -9.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Entera Bio Ltd's operating cash flow?
Entera Bio Ltd (ENTX) recorded an outflow of $7.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Entera Bio Ltd's total assets?
Entera Bio Ltd (ENTX) had $16.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Entera Bio Ltd's capital expenditures?
Entera Bio Ltd (ENTX) invested $107K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Entera Bio Ltd spend on research and development?
Entera Bio Ltd (ENTX) invested $6.0M in research and development during fiscal year 2025.
What is Entera Bio Ltd's current ratio?
Entera Bio Ltd (ENTX) had a current ratio of 6.94 as of fiscal year 2025, which is generally considered healthy.
What is Entera Bio Ltd's debt-to-equity ratio?
Entera Bio Ltd (ENTX) had a debt-to-equity ratio of 0.22 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Entera Bio Ltd's return on assets (ROA)?
Entera Bio Ltd (ENTX) had a return on assets of -71.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Entera Bio Ltd's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Entera Bio Ltd (ENTX) held $7.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.4M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Entera Bio Ltd's Altman Z-Score?
Entera Bio Ltd (ENTX) has an Altman Z-Score of 102.22, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Entera Bio Ltd's Piotroski F-Score?
Entera Bio Ltd (ENTX) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Entera Bio Ltd's earnings high quality?
Entera Bio Ltd (ENTX) reported a net loss of $11.4M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.